Previous Close | 4.5700 |
Open | 4.6000 |
Bid | 2.2600 x 1300 |
Ask | 4.6900 x 1100 |
Day's Range | 4.5100 - 4.6000 |
52 Week Range | 3.7200 - 6.1900 |
Volume | |
Avg. Volume | 56,796 |
Market Cap | 207.898M |
Beta (5Y Monthly) | 0.30 |
PE Ratio (TTM) | 12.08 |
EPS (TTM) | 0.3800 |
Earnings Date | Mar 13, 2023 - Mar 17, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.00 |
FDA Approval Currently Expected by Mid-2023Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021, with Gross Margins Over 50%Ability to Manufacture CYTOGAM at Kamada’s Facility to Positively Impact Plant Utilization and Efficiency REHOVOT, Israel and HOBOKEN, N.J. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it ha
Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.